Cholesterol and glaucoma: a systematic review and meta-analysis

Laura Posch-Pertl, Monja Michelitsch, Gernot Wagner, Brigitte Wildner, Günther Silbernagel, Gudrun Pregartner and Andreas Wedrich

ABSTRACT.

Purpose: Intraocular pressure is the main risk factor for glaucoma; however, additional risk factors may also matter. This systematic review and meta-analysis were conducted to summarize the evidence regarding the association of cholesterol parameters (total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels) and glaucoma.

Methods: Four electronic databases were searched for all publications containing ‘glaucoma’ and one of various forms of ‘cholesterol’ or ‘lipoprotein’. Two independent reviewers screened abstracts and potentially full texts of identified articles for eligibility. Risk of bias was assessed with the Newcastle–Ottawa Scale. A random-effects meta-analysis was used to investigate the differences in total cholesterol, LDL and HDL levels between patients with and without glaucoma.

Results: Overall, 29 observational studies were included in the systematic review and 26 reported quantitative information to investigate differences in cholesterol parameters between patients with glaucoma (N = 7196) and patients without glaucoma (N = 350 441). Patients with glaucoma had significantly higher total cholesterol levels than patients without glaucoma (Mean Difference (MD) 7.9 mg/dl, 95% CI 3.3 to 12.5, p = 0.001) and lower mean HDL levels (MD 2.0 mg/dl, 95% CI: -3.1 to -0.9, p = 0.001). Patients with glaucoma had higher mean LDL levels than patients without glaucoma, albeit not statistically significant (MD 6.1 mg/dl, 95% CI: -4.3 to 16.4, p = 0.251).

Conclusion: This systematic review and meta-analysis of observational studies found an association of glaucoma and high total cholesterol and low HDL levels, respectively. Although this supports the hypothesis that lipid levels pose an additional risk for glaucoma development, heterogeneity was substantial and causality cannot be presumed from identified observational studies.

Key words: cholesterol – glaucoma – high-density lipoproteins – low-density lipoproteins – statins

Introduction

Glaucoma is the most frequent cause of irreversible blindness worldwide. The main risk factor is intraocular pressure (IOP). Lowering of IOP may preserve the visual field in patients with glaucoma and thus remains the most important treatment strategy in glaucoma (Jonas et al. 2017). However, in some patients IOP lowering does not seem sufficient to stop progression of visual field loss. Therefore, other risk factors are currently investigated (Roddy 2020).

One of these additional risk factors is hypothesized to be lipid levels as polymorphisms in genes encoding proteins important for lipid metabolism such as ABCA1, GAS7 and ATXN2 have been associated with glaucoma (Wiggs & Pasquale 2017). Since a large case-control study found that long-term statin use was associated with a reduced risk of glaucoma interest in lipid levels as an additional risk factor has risen (McGwin et al. 2004). However, statins do not only lower lipid levels, but also seem to have an anti-inflammatory and consequently neuroprotective effect (Xu et al. 2017). This further obscures the relationship between glaucoma, lipid levels and lipid-lowering drugs.

The available data on the association between cholesterol and glaucoma are conflicting. Some studies found an association between cholesterol and...
glaucoma (Kim et al. 2014b), while other studies could not confirm this (Modrzejewska et al. 2015). Therefore, we conducted a systematic review and meta-analysis to summarize the evidence regarding the association of cholesterol parameters (total cholesterol, low-density lipoprotein and high-density lipoprotein levels) and glaucoma.

Methods

Registration
We registered our systematic review in International prospective register of systematic reviews (PROSPERO registration number CRD42017067748). The reporting in this publication follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (see Table S1).

Literature search
An experienced medical information specialist (BW) systematically searched the electronic databases: MEDLINE, Embase, Cochrane Central Register of Controlled Trials and Science Citation Index Expanded for all publications from database inception until October 2020. Additionally, all bibliographies of identified articles were scanned to identify potentially relevant manuscripts missed by our search in the databases. Using free term and controlled term formulations the following keywords were searched for in the databases: ‘glaucoma’ AND ‘cholesterol’, ‘glaucoma’ AND ‘low-density lipoprotein’, ‘glaucoma’ AND ‘high-density lipoprotein’, ‘glaucoma’ AND ‘dyslipidemia’ and ‘glaucoma’ AND ‘lipoprotein’. We limited our search to articles published in English.

Study eligibility criteria
All observational studies (cross-sectional, case-control, cohort, survey and surveillance reports) reporting the association between glaucoma and cholesterol including cross-sectional, case-control, cohort, survey and surveillance reports were included. Studies had to report on adult patients (≥18 years) and had to be published in English.

Abstracts and conference proceedings that are not published in peer-reviewed journals were not included. Furthermore, any publication without original data for the quantitative analysis was excluded for the quantitative meta-analysis.

Studies had to ascertain diagnosis of glaucoma by any one or more of the following: fundus photo, fundus examination, retinal nerve fibre layer (RNFL) thickness evaluation, visual field defects, medical records, self-report and/or glaucoma treatment.

Study selection
Two reviewers (LP, MM) independently screened references for inclusion. After pilot testing, we performed dual abstract screening based on the eligibility criteria. Included references underwent subsequent dual full-text review to decide on final inclusion or exclusion of the study. Disagreements were resolved by consensus. The online software ‘Covidence’ (Van der Mierden et al. 2019) was used for abstracts and full-text screening.

Data extraction
Two investigators (LP, MM) independently extracted the title, name of authors, year of publication, study design, sample size, type of glaucoma, definition of glaucoma and control patients, demographic data and outcome variables (i.e. total cholesterol, LDL, HDL). These data were recorded in a Microsoft Excel (Microsoft Cooperation) spreadsheet.

Risk of bias assessment
The Newcastle–Ottawa Scale (NOS) was used to assess potential risk of bias in each individual study (Hartling et al. 2013). The NOS was developed to assess the quality of nonrandomized studies. Two reviewers (LP, MM) independently assessed the included studies. Disagreements were solved by consensus.

Quantitative synthesis
Differences in total cholesterol, LDL and HDL levels between patients with and without glaucoma were analysed using random-effects meta-analysis. We extracted means and standard deviations from the studies whenever available. For one study reporting only the range, the standard deviation was estimated as (max−min)/6 due to a sufficiently large sample size (Wan et al. 2014). For studies with more than one glaucoma study arm (e.g. normal-tension glaucoma (NTG)), we used the weighted mean and pooled standard deviation to combine the arms. For studies with a healthy control group as well as a control group consisting of patients with PEX syndrome without glaucoma, only the healthy controls were considered. Mean differences (MD) between glaucoma and non-glaucoma patients are displayed in forest plots together with their 95% confidence intervals (CI). Possible publication bias was assessed using Egger’s linear regression test and Begg’s rank correlation test.

Furthermore, we performed leave-one-out analyses to assess the influence of each individual study on the overall results. Heterogeneity was assessed by means of the I² value. We tried to explain the heterogeneity through subgroup analyses by grouping studies into whether or not patients using lipid-lowering drugs or patients with diabetes were excluded. Finally, we performed meta-regression analyses to account for metric influential parameters; mean triglyceride levels, age, and BMI of patients as well as percentage of female patients were considered. Weighted means between the glaucoma and control groups were used to obtain one value per study.

All statistical analyses were performed using r version 3.5.1 (R Project for Statistical Computing, Vienna, Austria). In particular, the package ‘meta’ was used.

Results
Our search yielded 1496 references after removal of duplicates. Figure 1 shows details of the study selection process. After abstract screening, 167 full-text articles were assessed for eligibility. Most were deemed unfit due to different outcome parameters or study populations as well as ‘ineligible type of publication’. Finally, we included 29 studies in the qualitative synthesis and out of those 26 studies contained relevant information for the quantitative analysis.

Study characteristics
We included 26 studies investigating the difference in cholesterol levels (i.e.
total cholesterol, LDL and/or HDL) between patients with glaucoma ($N = 7196$) and patients without glaucoma ($N = 350441$). Seven studies included all glaucoma, six specifically NTG, five pseudoexfoliation (PEX) glaucoma, and four studies had two glaucoma arms (e.g. NTG and PEX glaucoma). Controls were recruited at the hospital in four studies, from the community in ten studies, and no recruitment method is given in eight studies (see Table 1 and 2).

**Study quality**

The NOS score ranged from 1 to 6 showing overall high risk of bias for all 22 studies included in the meta-analysis.

**Total cholesterol**

Twenty-three studies reported sufficient information to investigate differences in total cholesterol levels in patients with glaucoma ($N = 6751$) and patients...
without glaucoma (N = 328 397). The mean total cholesterol levels strongly varied between studies and ranged from 173.6 mg/dl in the study by Janicijevic et al. (2017) to 254.1 mg/dl in Walker et al. (1976).

Patients with glaucoma had significantly higher total cholesterol levels than patients without glaucoma (MD 7.9 mg/dl, 95% CI 3.3 to 12.5, p = 0.001; Fig. 2). However, there was substantial heterogeneity (I² = 86%, p < 0.01).

In the Baujat plot (see Fig. S1), one study seemed largely to contribute to overall heterogeneity (Janicijevic et al. 2017). When omitting this study, results remained significant (95% CI 1.4 to 8.2, p = 0.006). The study by Shon & Sung (2019) seemed to influence overall results greatly. Again, results remained significant (95% CI 3.4 to 14.0, p = 0.001) after omitting this study (Table 2).

To detect publication bias, Eggers test and Beggs test were performed. Both were not significant (p = 0.271, respectively 0.653) suggesting unbiased results.

Subgroup analysis revealed that studies excluding patients taking lipid-lowering drugs had a smaller mean absolute difference of total cholesterol levels between glaucoma patients and controls. In detail, studies excluding patients on lipid-lowering drugs showed an MD of 3.7 mg/dl (95% CI: −2.3 to 9.6) between glaucoma and control patients, and studies including patients on lipid-lowering drugs an MD of 8.8 mg/dl (95% CI 3.4 to 14.3).

Another subgroup analysis showed that studies excluding diabetics also had a smaller mean absolute difference. In detail, studies excluding diabetics had a MD of 4.6 mg/dl (95% CI: −0.5 to 9.7) between glaucoma patients and controls, studies with diabetics a MD of 5.6 mg/dl (95% CI: −2.1 to 13.4) and studies with no information of diabetics 13.9 mg/dl (95% CI: −5.6 to 33.3).

In meta-regression analysis, triglycerides (p = 0.277), age (p = 0.854), BMI (p = 0.518) and gender (p = 0.745) did not appear to modify the association between glaucoma and total cholesterol, but were also not able to explain the large heterogeneity.

**Low-density lipoproteins**

Fourteen studies provided information to investigate the difference in LDL levels in patients with glaucoma (N = 627) and patients without glaucoma (N = 822). The mean LDL levels strongly varied between studies and ranged from 104.1 mg/dl in the study by Rasoulinejad et al. (2015) to 155.5 mg/dl in Pavljasevic & Asceric (2009).

Patients with glaucoma had higher mean LDL levels than patients without glaucoma, albeit not statistically significant (MD 6.1 mg/dl, 95% CI: −4.3 to 16.4, p = 0.251; Fig. 3). Again, there was substantial heterogeneity (I² = 89%, p < 0.01).

In the Baujat plot (see Fig. S2) two studies, two studies seemed to largely contribute to overall heterogeneity and influence overall results (Modrzejewska et al. 2015; Janicijevic et al. 2017), when omitting these results were still not significant (95% CI: −6.3 to 14.7, p = 0.431, respectively 95% CI: −5.5 to 10.7, p = 0.528). Regarding publication bias, Eggers test and Beggs test were not significant (p = 0.153, respectively p = 0.87).

Subgroup analysis showed that studies excluding patients on lipid-lowering drugs had a smaller mean absolute difference (MD 4.3, 95% CI: −4.6 to 13.2) than studies including patients on

---

**Table 1. Overview of included studies, number of included glaucoma patients and controls.**

| Study                  | Total number | Glaucoma patients | Control patients | Total cholesterol | LDL | HDL |
|------------------------|--------------|-------------------|------------------|-------------------|-----|-----|
| Borger (Borger et al. 2003) | 5199         | 44                | 5155             | 1                 | 0   | 0   |
| Bossuyt (Bossuyt et al. 2015) | 63           | 30                | 33               | 1                 | 1   | 1   |
| Djordjevic-Jocic (Djordjevic-Jocic et al. 2014) | 291          | 33                | 258              | 1                 | 1   | 1   |
| Engin (Engin et al. 2010) | 191          | 160               | 31               | 1                 | 0   | 0   |
| Janicijevic (Janicijevic et al. 2017) | 80           | 40                | 40               | 1                 | 1   | 1   |
| Jung, (Jung et al. 2020) | 292 523      | 4970              | 287 553          | 1                 | 0   | 0   |
| Kim (Kim et al. 2016)   | 4186         | 124               | 4062             | 0                 | 0   | 1   |
| Kim 126 (Kim et al. 2014a) | 18 240       | 300               | 17 940           | 0                 | 0   | 1   |
| Kim 128 (Kim et al. 2014b) | 4095         | 80                | 4015             | 1                 | 0   | 1   |
| Kurlut (Kurtul et al. 2017) | 67           | 20                | 47               | 1                 | 1   | 1   |
| Lee (Lee et al. 2012)   | 80           | 45                | 35               | 1                 | 1   | 1   |
| Mirza (Mirza et al. 2020) | 63           | 21                | 42               | 0                 | 0   | 1   |
| Meier (Meier et al. 2018) | 9519         | 128               | 9391             | 1                 | 0   | 0   |
| Modrzejewska (Modrzejewska et al. 2015) | 110          | 56                | 54               | 1                 | 1   | 1   |
| Ogurel (Ogurel et al. 2016) | 54           | 19                | 35               | 1                 | 1   | 1   |
| Pavljasevic (Pavljasevic & Asceric, 2009) | 100          | 50                | 50               | 1                 | 1   | 1   |
| Rasoulinejad (Rasoulinejad et al. 2015) | 200          | 100               | 100              | 1                 | 1   | 1   |
| Shim (Shim et al. 2015) | 167          | 75                | 92               | 1                 | 0   | 0   |
| Shon (Shon & Sung, 2019) | 16 939       | 561               | 16 378           | 1                 | 0   | 1   |
| Su (Su et al. 2006)     | 80           | 40                | 40               | 1                 | 1   | 1   |
| Su (Su et al. 2007)     | 120          | 80                | 40               | 1                 | 1   | 1   |
| Türkylızm (Türkylızm et al. 2014) | 50          | 25                | 25               | 1                 | 1   | 1   |
| Walker (Walker et al. 1976) | 4983         | 63                | 4920             | 1                 | 0   | 0   |
| Yilmaz (Yılmaz et al. 2016) | 103          | 63                | 40               | 1                 | 1   | 1   |
| Yuki (Yuki et al. 2010) | 83           | 43                | 40               | 1                 | 0   | 0   |
| Yüksel (Yüksel et al. 2010) | 51           | 26                | 25               | 1                 | 1   | 1   |
| Study                  | Glaucoma type | Glaucoma definition                                                                 | Control type                                                                 | Origin of study                                                                 | Age (Mean) | Female (%) | BMI* (Mean) | Lipid-lowering medication (%) | Diabetes (%) | CVD (%) | Smokers (ever) (%) |
|-----------------------|---------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------|------------|--------------|-------------------------------|--------------|----------|-------------------|
| Borger (Borger et al. 2003) | OAG           | Glaucomatous optic neuropathy and glaucomatous visual field defect                   | Population within Rotterdam Study                                             | Netherlands                                                                   | 72         | 69         | 48           | 60                           | n/d          | 26       | 16                |
| Bossuyt (Bossuyt et al. 2015) | NTG          | Neuroretinal rim loss and typical visual field defect and normal IOP < 21 mmHg     | Local community                                                                | Netherlands                                                                   | 65         | 67         | 77           | 76                           | 26           | 27       | 21                |
| Djordjevic-Jocic (Djordjevic-Jocic et al. 2014) | Glaucoma     | Definition by Foster (Foster et al. 2002)                                          | Outpatient Department (Nephrology and Haemodialysis)                          | Serbia                                                                       | 66         | 64         | 61           | 45                           | n/d          | 28       | 27                |
| Engin (Engin et al. 2010) | Glaucoma      | No dear definition given                                                               | n/d                                                                           | Turkey                                                                       | 51         | 45         | 66           | 48                           | n/d          | 26       | 10                |
| Janicijevic (Janicijevic et al. 2017) | PEX glaucoma | Elevated IOP and optic disc glaucomatous changes and functional failure of the visual field | n/d                                                                           | Serbia                                                                       | 71         | 68         | 35           | 57                           | n/d          | 25       | 4                 |
| Jung, (Jung et al. 2020) | Incident Glaucoma | No dear definition given                                                                | Health Insurance (KNHIS***)                                                   | South Korea                                                                  | 32         | 31         | 50           | 58                           | 48           | 23       | 23                |
| Kim (Kim et al. 2016)  | Glaucoma      | Definition by Foster (Foster et al. 2002)                                            | Glaucoma Screening Programme (Seoul National University Hospital)             | South Korea                                                                  | 50         | 40         | 35           | 51                           | n/d          | 24       | 10                |
| Kim 126 (Kim et al. 2014a) | NTG          | IOP level below 22 mmHg and normal open anterior chamber angle and the presence of glaucomatous optic nerve head change and corresponding visual field change | Glaucoma Screening Programme (Seoul National University Hospital)             | South Korea                                                                  | 54         | 53         | 32           | 43                           | n/d          | 24       | 24                |
| Kim 128 (Kim et al. 2014b) | NTG          | Definition by Foster (Foster et al. 2002)                                            | Glaucoma Screening Programme (Seoul National University Hospital)             | South Korea                                                                  | 32         | 31         | 50           | 58                           | 48           | 23       | 23                |
| Kurtul (Kurtul et al. 2017) | PEX glaucoma | Presence of exfoliation material in the anterior chamber and IOP over 21 mmHg and open anterior chamber angle and visual field changes and optic nerve changes | Outpatient Department (KNHANES17)                                            | Turkey                                                                       | 71         | 68         | 35           | 57                           | n/d          | 25       | 4                 |
| Lee (Lee et al. 2012)   | NTG          | Open anterior chamber angles and IOP < 22 mmHg and glaucomatous optic disc cupping and visual field defects | Glaucoma clinic                                                               | South Korea                                                                  | 54         | 52         | 51           | 49                           | n/d          | 26       | 26                |
| Mirza (Mirza et al. 2020) | PEX glaucoma | Presence of PEX material and IOP ≥ 21 mmHg and open anterior chamber angle and visual field changes, and presence of cup to disc ratio > 0.5 and glaucomatous changes in the optic disc and in the visual field | Ophthamology Department (KNHANES)                                            | Turkey                                                                       | 68         | 67         | 48           | 43                           | n/d          | 25       | 4                 |
| Meier (Meier et al. 2018) | Incident Glaucoma | No dear definition given                                                                | Preventive medical examination (Aerobics Center)                             | United States of America                                                     | 54         | 50         | 19           | 19                           | n/d          | 26       | 26                |
| Study | Glaucoma type | Glaucoma definition | Control type | Origin of study | Study details |
|-------|---------------|---------------------|--------------|----------------|---------------|
| Modrzejewska (Modrzejewska et al. 2015) | Glaucoma patients | Treated with antiglaucomatous beta-blocker topical drops and typical glaucomatous optic disc and visual field changes and visual field loss and intraocular pressure elevation | Healthy volunteers | Poland | Longitudinal Study (Modrzejewska et al. 2015) |
| Ogurel (Ogurel et al. 2016) | PEX glaucoma | Presence of exfoliation materials and raised IOP | Outpatient | Turkey | PEX glaucoma (Ogurel et al. 2016) |
| Pavljasevic & Asceric, 2009 | POAG | IOP > 20 mmHg and visual field changes and open angle | Ophthalmology Department | Bosnia and Herzegovina | Pavljasevic & Asceric, 2009 |
| Rasoulinejad et al. (2015) | POAG | Definition by Foster (Foster et al. 2002) | Ophthalmology Department | Iran | Rasoulinejad et al. (2015) |
| Shim et al. (2015) | NTG | Disc haemorrhage and open angle and glaucomatous optic disc abnormality and glaucomatous visual field loss and IOP < 21mm Hg | Outpatient | South Korea | Shim (Shin et al. 2015) |
| Shon & Sung, 2019 | Glaucoma | No clear definition given | Survey (KNHANES ††) | South Korea | Shon (Shon & Sung, 2019) |
| Su et al. (2006) | NTG | Untreated IOP < 22 mm Hg and open anterior chamber angles and typical glaucomatous optic nerve-related visual field loss and visual field loss | Routine physical check-up | Taiwan | Su (Su et al. 2006) |
| Turkyilmaz et al. (2014) | NTG and PEX glaucoma | IOP ≤ 21 mmHg, respectively IOP > 21 mmHg and exfoliation material nad and glaucomatous optic disc cupping and characteristic optic nerve-related visual field loss | Routine physical check-up | Turkey | Turkyilmaz et al. (2014) |
| Walker et al. (1976) | NTG and POAG | No clear definition given | Survey | United Kingdom | Walker et al. (1976) |
| Yilmaz et al. (2016) | NTG and PEX glaucoma | IOP > 21 mmHg and exfoliation material nad and glaucomatous optic disc cupping and characteristic optic nerve-related visual field loss | Routine physical check-up | Turkey | Yilmaz et al. (2016) |

†† KNHANES: Korean National Health and Nutrition Examination Survey
Table 2 (Continued)

| Study | Glaucoma type | Glaucoma definition | Control type | Origin of study | Age (Mean) | Female (%) | BMI* (Mean) | Lipid-lowering medication (%) | Diabetes (%) | CVD† (%) | Smokers (ever) (%) |
|-------|---------------|---------------------|--------------|-----------------|------------|------------|-------------|-------------------------------|--------------|-----------|-----------------|
| Yüksel (Yuksel et al. 2010) | PEX glaucoma | and the presence of a nerve fibre layer defect and visual field defect Glaucomatous optic neuropathy and visual field damage and PEX material and an intraocular pressure of > 22 mmHg without treatment | Ophthalmology Department | Turkey | 66 | 65 | 31 | 48 | 27 | 28 | excl | excl | excl | excl | excl | excl | excl | excl | excl | excl | excl |

* Body Mass Index.
† Cardiovascular disease.
‡ Glaucoma patients (G) and control patients (C).
§ Excluded in respective study population.
¶ Numbers of active smokers.
** Korean Health Insurance System.
†† Population-based cross-sectional survey performed by the Korea Centers for Disease Control and Prevention.
lipid-lowering drugs (MD 6.1, 95% CI: −8.6 to 20.8).

High-density lipoproteins

Nineteen studies contained information to investigate the difference in HDL levels in patients with glaucoma (N = 1713) and patients without glaucoma (N = 43 259). The mean HDL levels strongly varied between studies and ranged from 41.1 mg/dl in the study by Modrzejewska et al. (2015) to 72.1 mg/dl in Bossuyt et al. (2015). Patients with glaucoma had lower mean HDL levels (MD −0.7, 95% CI: −3.3 to 1.9, p = 0.001; Fig. 4) than patients without glaucoma and the heterogeneity was substantial (I² = 69%, p < 0.01).

One study in particular (Kim et al. 2016) had an influence on overall results (see Fig. S3). Results remained significant after omission of this study (95% CI: −3.0 to −0.4, p = 0.013). Three studies contributed largely to overall heterogeneity (Kim et al. 2014b; Yilmaz et al. 2016; Shon & Sung, 2019). Again, after omitting this study, results remained significant (95% CI: −3.0 to −0.4, p = 0.004; 95% CI: −3.3 to −0.8, p = 0.001, respectively 95% CI: −3.4 to −1.2, p < 0.001). For HDL results Eggers test was significant (p = 0.003), while Beggs test was not (p = 0.753).

Subgroup analysis showed that studies excluding patients on lipid-lowering drugs had a smaller mean absolute difference (MD −0.7, 95% CI: −3.5 to 2.1) than studies including patients on lipid-lowering drugs (MD −2.5, 95% CI: −3.8 to −1.1).

In meta-regression, triglycerides modified the association between HDL and glaucoma (p = 0.007). Age (p = 0.291), BMI (p = 0.235) and gender (p = 0.238) did not modify the association between HDL and glaucoma.

**Discussion**

This systematic review and meta-analysis of observational studies found that patients with glaucoma had higher mean total cholesterol levels and lower HDL levels than patients without glaucoma, whereas there was no significant difference regarding LDL. This may support the conjecture that total cholesterol levels and HDL levels pose an additional risk factor for glaucoma. However, no causality can be drawn from observational studies.

The studies on the association between glaucoma and lipid levels included in our systematic review found different results, which resulted in high heterogeneity across studies in the meta-analyses. There are several possible reasons for this. First of all, different types of glaucoma were included. Secondly, there were differences in inclusion criteria among the individual studies. Furthermore, the exclusion criteria of individual studies differed greatly. For example, some studies excluded patients with lipid-lowering drugs, while others included them or did not report on the use of lipid-lowering medications (see Table 1).

Subgroup analysis showed that studies excluding patients on lipid-lowering drugs showed smaller mean differences in total cholesterol levels and HDL levels between glaucoma and control patients. It has been suggested that statin use reduces the incidence of glaucoma (McCann et al. 2016). Therefore, confounding by indication is a possibility in this meta-analysis and

---

**Fig. 2.** Random-effects meta-analysis on total cholesterol level differences between glaucoma patients and controls. The differences are expressed on an absolute scale, that is mg/dl.
our findings may be exaggerated. Otherwise it could be that patients taking lipid-lowering drugs have high cholesterol and thus studies excluding these patients had smaller mean differences. This would support our notion that cholesterol plays a role in the development of glaucoma.

Statin use has been shown to protect against glaucoma development and progression. It seems that the beneficial effect of statins is associated less with lowering lipid levels and more with other properties of statins such as possible anti-inflammatory properties (Talwar et al. 2017). In this meta-analysis, LDL levels were not associated with glaucoma, which might support the concept that statin lowers the glaucoma risk via other mechanism than lowering lipid levels. As our study found that HDL and total cholesterol levels were associated with glaucoma, it might be interesting to see whether statins, which additionally increase HDL levels such as pitavastatin (Pirillo & Catapano, 2017), may be even better in reducing glaucoma development than statins pre-eminently reducing LDL.
Topical beta-blockers seem to lower HDL (Stewart et al. 1999) (Yamamoto et al. 1996). This was confirmed in the Blue Mountains Eye study, although the adverse effect on HDL was seen exclusively in men (Mitchell et al. 2000). Most of the included studies did not report on topical treatment used and thus no meta-regression could be performed. It may be assumed that a large number of patients use topical beta-blockers and the effect seen in this meta-analysis is due to this side effect.

We want to mention several limitations of this meta-analysis. Firstly, we only included observational studies. Observational data cannot prove causality. Further, there is some evidence that cholesterol influences IOP (Wang et al. 2019). Therefore, this study cannot answer whether cholesterol leads to glaucoma via IOP or whether this association is independent of IOP. Secondly, there was a large heterogeneity between studies concerning types of studies, inclusion and exclusion criteria and the selection of the control group. Additionally, Egger’s test was significant in our meta-analysis on HDL and glaucoma suggesting publication bias. Thirdly, statin use is a potential confounder in this study, which could not be fully accounted for.

Another potential bias are errors in the diagnosis of glaucoma, that is, glaucoma cases were misidentified as normal and vice-versa. Finally, our results were statistically significant. However, mean absolute differences in total cholesterol and HDL were still small (MD 9.2 mg/dl, respectively –2.3 mg/dl) and thus, of unclear clinical relevance.

In conclusion, this meta-analysis of observational studies found an association of glaucoma and high total cholesterol and low HDL levels, respectively. Although this supports the hypothesis that lipid levels pose an additional risk for glaucoma development, we were unable to explain the large heterogeneity and causality can generally not be presumed from identified observational studies.

References

Borger PH, van Leeuwen R, Hulsman CA, Wollfs RC, van der Kuip DA, Hofman A & de Jong PT (2003): Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology 110: 1292–1296.

Bosuay J, Vandekerckhove G, De Backer TL et al. (2013): Vascular dysregulation in normal-tension glaucoma is not affected by structure and function of the microcirculation or macrocirculation at rest: a case-control study. Medicine 94: e425.

Djordjevic-Jocic J, Cukurkanovic R, Mitic B et al. (2014): Ocular and systemic factors associated with glaucoma in chronic kidney disease patients. Int Urol Nephrol 46: 2191–2198.

Engin KN, Yemisci B, Yigit U, Agachan A & Coskun C (2010): Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients. Molecular vision 16: 1260–1271.

Foster PJ, Buhrmann R, Quigley HA & Johnson GJ (2002): The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 86: 238–242.

Hartling L, Milne A, Ham MP, Vandermeer B, Ansari M, Tsertasvdaze A & Dryden DM (2013): Testing the Newcastle–Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol 66: 982–993.

Janicijevic K, Kocic S, Pajovic S, Zdravkovic N, Sarenac-Vulovic T & Janicijevic-Petrovic M (2017): The importance of developing atherosclerosis in pseudoexfoliation glaucoma. Vojnosanit Pregl 74: 8–12.

Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R & Panda-Jonas S (2017): Glaucoma. Lancet 390: 2183–2193.

Jung Y, Han K, Park HYL, Lee SH & Park CK (2020): Metabolic health, obesity, and the risk of developing open-angle glaucoma: metabolically healthy obese patients versus metabolically unhealthy but normal weight patients. Diabetes Metab J 44: 414–425.

Kim GA, Park SH, Ko J, Lee JH, Bae HW, Seong GJ & Kim CY (2016): Albuminuria is associated with open-angle glaucoma in nondiabetic Korean subjects: a cross-sectional study. PLoS One 11: e0168682.

Kim M, Jeoung JW, Park KH, Oh WH, Choi HJ & Kim DM (2014a): Metabolic syndrome as a risk factor in normal-tension glaucoma. Acta Ophthalmol 92: e637–e643.

Kim MJ, Kim MJ, Kim HS, Jeoung JW & Park KH (2014b): Risk factors for open-angle glaucoma with normal baseline intraocular pressure in a young population: the Korea National Health and Nutrition Examination Survey. Clin Exp Ophthalmol 42: 825–832.

Kurtul BE, Kurtul A, Altayilik Ozer P, Kabatas EU & Ertugrul GT (2017): Serum lipid levels in pseudoexfoliation syndrome. Semin Ophthalmol 32: 281–284.

Lee NY, Park HY, Park CK & Ahn MD (2012): Analysis of systemic endothelin-1, matrix metalloproteinase-9, macrophage chemotactant protein-1, and high-sensitivity C-reactive protein in normal-tension glaucoma. Curr Eye Res 37: 1121–1126.

Liberati A, Altman DG, Tetzlaff J et al. (2009): The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.

McCann P, Hogg RE, Fallis R & Azaurre-Blanco A (2016): The effect of statins on intraocular pressure and on the incidence and progression of glaucoma: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci 57: 2729–2748.

McGwin G Jr, McNeal S, Owseyl C, Girklin C, Epstein D & Lee PP (2004) Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol 122: 822–826.

Meier NF, Lee DC, Sui X & Blair SN (2018): Physical activity, cardiorepiratory fitness, and incident glaucoma. Med Sci Sports Exerc 50: 2253–2258.

Mirza E, Oltulu R, Katipoglu Z, Mirza GD & Ozkaginca A (2020): Monocyte/HDL ratio and lymphocyte/monozyt ratio in patients with pseudoexfoliation syndrome. Ocul Immunol Inflamm 28: 142–146.

Mitchell P, Wang JJ, Cumming RG, House P & England JD (2000): Long-term topical timolol and blood lipids: the Blue Mountains Eye Study. J Glaucoma 9: 174–178.

Modrzewskas M, Grzesiek W, Zaborksi D & Modrzewska A (2015): The role of lipid dysregulation and vascular risk factors in glaucomatous retrolubar circulation. Bosn J Basic Med Sci 15: 50–56.

Ogurel T, Ogurel R, Topuz M, Ornek N & Ornek K (2016): Plasma adiponin level in patients with pseudoexfoliation. Int Ophthalmol 36: 737–742.

Pavlajsevic S & Asercic M (2009): Primary open-angle glaucoma and serum lipids. Bosn J Basic Med Sci 9: 85–88.

Pirillo A & Catapano AL (2017): Pitavastatin and HDL: effects on plasma levels and function(s). Atheroscler Suppl 27: e1–e9.

Rasoulinejad SA, Kasiri A, Montazeri M, Rashidi N, Montazeri M, Montazeri E & Hedayati H (2015): The association between primary open angle glaucoma and clustered components of metabolic syndrome. Open Ophthalmol J 9: 149–155.

Roddy GW (2020): Metabolic syndrome is associated with ocular hypertension and glaucoma. J Glaucoma 29: 726–731.

Shim SH, Kim CY, Kim JM, Kim DY, Kim YJ, Bae JH & Sung KC (2015): The role of systemic arterial stiffness in open-angle glaucoma with diabetes mellitus. Biomed Res Int 2015: 428535.

Shon K & Sung KR (2019): Dyslipidemia, dyslipidemia treatment, and open-angle glaucoma in the Korean national health
and nutrition examination survey. J Glaucoma 28: 550–556.
Stewart WC, Dubiner HB, Mundorf TK et al. (1999): Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol 127: 142–147.
Su WW, Cheng ST, Hsu TS & Ho WJ (2006): Abnormal flow-mediated vasodilation in normal-tension glaucoma using a noninvasive determination for peripheral endothelial dysfunction. Invest Ophthalmol Vis Sci 47: 3390–3394.
Su WW, Ho WJ, Cheng ST, Chang SH & Wu SC (2007): Systemic high-sensitivity C-reactive protein levels in normal-tension glaucoma and primary open-angle glaucoma. J Glaucoma 16: 320–323.
Talwar N, Musch DC & Stein JD (2017): Association of daily dosage and type of statin agent with risk of open-angle glaucoma. JAMA Ophthalmol 135: 263–267.
Turkyilmaz K, Oner Y, Cicak Y, Kurt A & Durmus M (2014): Systemic arterial stiffness in patients with pseudoexfoliation glaucoma. J Glaucoma 23: e108–e111.
Van der Mierden S, Tsaioun K, Bleich A & Leenaars CHC (2019): Software tools for literature screening in systematic reviews in biomedical research. Altex 36: 508–517.
Walker WM, Walton KW, Magnani HN, Marsters JB & Ward EG (1976): Glaucouma and ischaemic vascular disease risk factors. Trans Ophthalmol Soc U K 96: 237–240.
Wan X, Wang W, Liu J & Tong T (2014): Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14: 135.
Wang YX, Tao JX & Yao Y (2019): The association of intraocular pressure with metabolic syndrome and its components: a meta-analysis and systematic review. Int J Ophthalmol 12: 510–516.
Wiggs JL & Pasquale LR (2017): Genetics of glaucoma. Hum Mol Genet 26: R21–R27.
Xu X, Gao W, Cheng S et al. (2017): Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J Neuroinflammation 14: 167.
Yamamoto T, Kitazawa Y, Noma A et al. (1996): The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma 5: 252–257.
Yilmaz N, Coban DT, Bayindir A et al. (2016): Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoexfoliative glaucoma. Bosn J Basic Med Sci 16: 21–27.
Yuki K, Murat D, Kimura I & Tsubota K (2010): Increased serum total antioxidant status and decreased urinary 8-hydroxy-2'-deoxyguanosine levels in patients with normal tension glaucoma. Acta Ophthalmol 88: e259–e264.
Yuksel N, Pirhan D, Altintas O & Caglar Y (2010): Systemic high-sensitivity C-reactive protein level in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. J Glaucoma 19: 373–376.

Received on April 13th, 2020. Accepted on December 27th, 2020.

Correspondence:
Laura Posch-Pertl, MD
Department of Ophthalmology
Medical University of Graz
Auenbruggerplatz 4
A-8036 Graz
Austria
Tel: 0043-316-385 80821
Fax: 0043-316-385 13261
Email: laura.pertl@medunigraz.at

PROSPERO registration number CRD42017067748

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Baujat- and Funnel-Plot for meta-analysis on total cholesterol and glaucoma.
Figure S2. Baujat- and Funnel-Plot for meta-analysis on LDL and glaucoma.
Figure S3. Baujat- and Funnel-Plot for meta-analysis on HDL and glaucoma.
Table S1. PRISMA Checklist. Adapted from Moher et al. (2009), Liberati et al. (2009).